# TRIM-EBC (NCT06517212)

> Tirzepatide Weight Loss for MRD+ Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06517212
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Baylor Research Institute
- Conditions: Breast Cancer; Breast Neoplasms; Breast Cancers
- Interventions: Tirzepatide
- Enrollment: 48
- Primary outcome: ctDNA efficacy
- Primary outcome: distant disease-free survival efficacy

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trim-ebc-nct06517212